<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1560-4381</journal-id>
<journal-title><![CDATA[Correo Científico Médico]]></journal-title>
<abbrev-journal-title><![CDATA[ccm]]></abbrev-journal-title>
<issn>1560-4381</issn>
<publisher>
<publisher-name><![CDATA[Universidad Ciencias Médicas de Holguín]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1560-43812020000100341</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Papel de las citoquinas en la fisiopatología de la artritis reumatoide]]></article-title>
<article-title xml:lang="en"><![CDATA[Role of cytokines in the physiopathology of rheumatoid arthritis]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Feria Díaz]]></surname>
<given-names><![CDATA[Gisela Eduarda]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Leyva Proenza]]></surname>
<given-names><![CDATA[Carlos Alberto]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Concepción Parra]]></surname>
<given-names><![CDATA[Walquiris]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Castro Maquilón]]></surname>
<given-names><![CDATA[Andrea Geraldine]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Larrea Meza]]></surname>
<given-names><![CDATA[Ivonne Silvana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Escuela Superior Politécnica de Chimborazo  ]]></institution>
<addr-line><![CDATA[Riobamba ]]></addr-line>
<country>Ecuador</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Centro Clínico-Quirúrgico Ambulatorio Hospital del Día Norte Tarqui ]]></institution>
<addr-line><![CDATA[Guayas ]]></addr-line>
<country>Ecuador</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Hospital General Guasmo Sur  ]]></institution>
<addr-line><![CDATA[Guayas ]]></addr-line>
<country>Ecuador</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>03</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>03</month>
<year>2020</year>
</pub-date>
<volume>24</volume>
<numero>1</numero>
<fpage>341</fpage>
<lpage>360</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S1560-43812020000100341&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S1560-43812020000100341&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S1560-43812020000100341&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN La artritis reumatoide es una enfermedad sistémica crónica de etiología multifactorial que afecta las articulaciones. Su fisiopatología no es bien conocida, pero indica que existe un papel relevante de las citoquinas como moléculas que interrelacionan los trastornos del sistema inmune y el neuroendocrino con factores ambientales. En esta revisión se describe el papel de las citoquinas proinflamatorias en la fisiopatología de la artritis reumatoide y la aplicación práctica de estos conocimientos en el diseño de nuevos medicamentos para el tratamiento de esta enfermedad. Para ello se revisaron las bases de datos MedLine, MedicalKey y SciELO con los descriptores citoquinas y artritis reumatoide en español e inglés. Se filtraron principalmente para los artículos citables publicados en los últimos 5 años. También se revisaron las revistas biomédicas cubanas.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT Rheumatoid arthritis is a chronic systemic disease of multifactorial etiology that affects the joints. Its physiopathology is not well known, but it indicates that there is a relevant role of cytokines as molecules which interrelate immune and neuroendocrine system disorders with environmental factors. This review describes the role of proinflammatory cytokines in the physiopathogenesis of rheumatoid arthritis and the practical application of this knowledge in the design of new medications for the treatment of this disease. For this work MedLine, MedicalKey and SciELO databases were reviewed with the descriptors cytokines and rheumatoid arthritis in Spanish and English. They were filtered mainly for quotable articles published in the last 5 years. Cuban biomedical journals were also reviewed.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[artritis reumatoide]]></kwd>
<kwd lng="es"><![CDATA[citoquinas]]></kwd>
<kwd lng="es"><![CDATA[fisiopatología]]></kwd>
<kwd lng="es"><![CDATA[autoinmunidad]]></kwd>
<kwd lng="es"><![CDATA[inflamación]]></kwd>
<kwd lng="en"><![CDATA[rheumatoid arthritis]]></kwd>
<kwd lng="en"><![CDATA[cytokines]]></kwd>
<kwd lng="en"><![CDATA[physiopathology]]></kwd>
<kwd lng="en"><![CDATA[autoimmunity]]></kwd>
<kwd lng="en"><![CDATA[inflammation]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sansaricq Coto]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Céspedes Miranda]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Molinet Fuertes]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Peña Sánchez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Indicadores biológicos y de estrés oxidativo en la evolución de pacientes con artritis reumatoide]]></article-title>
<source><![CDATA[Rev Cubana Reumatol]]></source>
<year>2015</year>
<volume>17</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>132-8</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mendoza Coussette]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Alonso Biosca]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Predicción del riesgo coronario en la Artritis Reumatoide mediante variables asociadas a su actividad inmunológica]]></article-title>
<source><![CDATA[Rev Cubana Invest Bioméd]]></source>
<year>2018</year>
<volume>37</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martínez-Ferrer]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Aguilar Zamora]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Montolio Chiva]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Valls Pascual]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Ybáñez García]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Alegre Sancho]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tofacitinib una nueva molécula en el tratamiento de la artritis reumatoide]]></article-title>
<source><![CDATA[Rev Soc Val Reuma]]></source>
<year>2018</year>
<volume>7</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>12-8</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ridgley]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Anderson]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
<name>
<surname><![CDATA[Pratt]]></surname>
<given-names><![CDATA[AG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[What are the dominant cytokines in early rheumatoid arthritis?]]></article-title>
<source><![CDATA[Curr Opin Rheumatol]]></source>
<year>2018</year>
<volume>30</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>207-14</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carrión]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Frommer]]></surname>
<given-names><![CDATA[KW]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez-García]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Müller-Ladner]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Gomariz]]></surname>
<given-names><![CDATA[RP]]></given-names>
</name>
<name>
<surname><![CDATA[Neumann]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Adipokine Network in Rheumatic Joint Diseases]]></article-title>
<source><![CDATA[Int J Mol Sci]]></source>
<year>2019</year>
<volume>20</volume>
<page-range>4091</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Malemud]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Defective T-Cell Apoptosis and T-Regulatory Cell Dysfunction in Rheumatoid Arthritis]]></article-title>
<source><![CDATA[Cells]]></source>
<year>2018</year>
<volume>7</volume>
<page-range>223</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chang]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
<name>
<surname><![CDATA[Nigrovic]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antibody-dependent and -independent mechanisms of inflammatory arthritis]]></article-title>
<source><![CDATA[JCI Insight]]></source>
<year>2019</year>
<volume>4</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>125-278</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Ouyang]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Xie]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Liang]]></surname>
<given-names><![CDATA[ZH]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[XW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Serum DKK-1 level in the development of ankylosing spondylitis and rheumatic arthritis: a meta-analysis]]></article-title>
<source><![CDATA[Exp Mol Med]]></source>
<year>2016</year>
<volume>48</volume>
<page-range>228</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tateiwa]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Yoshikawa]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Kaito]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cartilage and Bone Destruction in Arthritis: Pathogenesis and Treatment Strategy: A Literature Review]]></article-title>
<source><![CDATA[Cel]]></source>
<year>2019</year>
<volume>8</volume>
<page-range>818</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Put]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Westhovens]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Lahoutte]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Matthys]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Molecular imaging of rheumatoid arthritis: emerging markers, tools, and techniques]]></article-title>
<source><![CDATA[Arthr Res Ther]]></source>
<year>2014</year>
<volume>16</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>208</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[González Costa]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[González Alexander]]></surname>
<given-names><![CDATA[AP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[La inflamación desde una perspectiva inmunológica: desafío a la Medicina en el siglo XXl]]></article-title>
<source><![CDATA[Rev Habanera Cienc Méd]]></source>
<year>2019</year>
<volume>18</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>30-44</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[KW]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[HR]]></given-names>
</name>
<name>
<surname><![CDATA[Kim BM Cho]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Th17 Cytokines Regulate Osteoclastogenesis in Rheumatoid Arthritis]]></article-title>
<source><![CDATA[Am J Pathol]]></source>
<year>2015</year>
<volume>185</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>3011-24</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bui]]></surname>
<given-names><![CDATA[VL]]></given-names>
</name>
<name>
<surname><![CDATA[Brahn]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cytokine targeting in rheumatoid arthritis]]></article-title>
<source><![CDATA[Clin Immunol]]></source>
<year>2019</year>
<volume>206</volume>
<page-range>3-8</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alam]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Jantan]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Bukhari]]></surname>
<given-names><![CDATA[SNA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rheumatoid arthritis: Recent advances on its etiology, role of cytokines and pharmacotherapy]]></article-title>
<source><![CDATA[Biomed Pharmacoth]]></source>
<year>2017</year>
<volume>92</volume>
<page-range>615-33</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Virtanen]]></surname>
<given-names><![CDATA[AT]]></given-names>
</name>
<name>
<surname><![CDATA[Haikarainen]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Raivola]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Silvennoinen]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases]]></article-title>
<source><![CDATA[BioDrugs]]></source>
<year>2019</year>
<volume>33</volume>
<page-range>15-32</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Borriello]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Galdiero]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Varricchi]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Loffredo]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Spadaro]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Marone]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Innate Immune Modulation by GM-CSF and IL-3 in Health and Disease]]></article-title>
<source><![CDATA[Int J Mol Sci]]></source>
<year>2019</year>
<volume>20</volume>
<page-range>834</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Coury]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Peyruchaud]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Machuca-Gayet]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Osteoimmunology of Bone Loss in Inflammatory Rheumatic Diseases]]></article-title>
<source><![CDATA[Front Immunol]]></source>
<year>2019</year>
<volume>10</volume>
<page-range>679</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mendez-Rayo]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Ochoa-Zárate]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Posso-Osorio]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Ortiz]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Naranjo-Escobar]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Tdbón Gabriel]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Interpretación de los autoanticuerpos en enfermedades reumatológicas]]></article-title>
<source><![CDATA[Rev Colomb Reumatol]]></source>
<year>2018</year>
<volume>25</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>112-25</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fang]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Ou]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Nandakumar]]></surname>
<given-names><![CDATA[KS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Autoantibodies as Diagnostic Markers and Mediator of Joint Inflammation in Arthritis]]></article-title>
<source><![CDATA[Mediators Inflamm]]></source>
<year>2019</year>
</nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bugatti]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Manzo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Montecucco]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Caporali]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Clinical Value of Autoantibodies in Rheumatoid Arthritis]]></article-title>
<source><![CDATA[Front Med (Lausanne)]]></source>
<year>2018</year>
<volume>5</volume>
<page-range>339</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hernández-Bello]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Baños-Hernández]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Palafox-Sánchez]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Navarro-Zarza]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Reyes-Castillo]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Muñoz Valle]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Combinaciones de autoanticuerpos y su asociación con variables clínicas en artritis reumatoidea]]></article-title>
<source><![CDATA[Act Bioquím Clín Latinoam]]></source>
<year>2018</year>
<volume>52</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>49-60</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Muñoz-Grajales]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Muñoz Vahos]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
<name>
<surname><![CDATA[Díaz Betancur]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ramírez Gómez]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Frecuencia de anticuerpos antipéptido cíclico citrulinado y factor reumatoide en pacientes con enfermedades reumatológicas de un centro de reumatología, Medellín, Colombia]]></article-title>
<source><![CDATA[Rev Colombiana Reumatol]]></source>
<year>2014</year>
<volume>21</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>177-82</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hernández-Flórez]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Valor]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[IL-6: su papel en la patogenia de la artritis reumatoide. Consecuencias clínicas]]></article-title>
<source><![CDATA[Reumatol Clin]]></source>
<year>2018</year>
<volume>14</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>7-10</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jung]]></surname>
<given-names><![CDATA[JY]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[MY]]></given-names>
</name>
<name>
<surname><![CDATA[Suh]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[HA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Off-label use of tocilizumab to treat non-juvenile idiopathic arthritis in pediatric rheumatic patients: a literature review]]></article-title>
<source><![CDATA[Pediatr Rheumatol]]></source>
<year>2018</year>
<volume>16</volume>
<numero>79</numero>
<issue>79</issue>
<page-range>1-9</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Evans-Marin]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Rogier]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Koralov]]></surname>
<given-names><![CDATA[SB]]></given-names>
</name>
<name>
<surname><![CDATA[Manasson]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Roeleveld]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[van der Kraan]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Microbiota-Dependent Involvement of Th17 Cells in Murine Models of Inflammatory Arthritis]]></article-title>
<source><![CDATA[Arthritis Rheumatol]]></source>
<year>2018</year>
<volume>70</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1971-83</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Serra López-Matencio]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Morell Baladrón]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Castañeda]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[JAK-STAT inhibitors for the treatment of immunomediated diseases]]></article-title>
<source><![CDATA[Med Clín]]></source>
<year>2019</year>
<volume>152</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>353-60</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Biggioggero]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Crotti]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Becciolini]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Favalli]]></surname>
<given-names><![CDATA[EG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection]]></article-title>
<source><![CDATA[Drug Des Devel Ther]]></source>
<year>2019</year>
<volume>13</volume>
<page-range>57-70</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Camacho Castillo]]></surname>
<given-names><![CDATA[KP]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez Verdezoto]]></surname>
<given-names><![CDATA[TD]]></given-names>
</name>
<name>
<surname><![CDATA[Ortiz Granja]]></surname>
<given-names><![CDATA[LB]]></given-names>
</name>
<name>
<surname><![CDATA[Urbina Aucancela]]></surname>
<given-names><![CDATA[KD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Artritis reumatoidea en el adulto mayor]]></article-title>
<source><![CDATA[Rev Cubana de Reumatolo]]></source>
<year>2019</year>
</nlm-citation>
</ref>
<ref id="B29">
<label>29.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Smolen]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Landewé]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Bijlsma]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Burmester]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Chatzidionysiou]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Maxime Dougados]]></surname>
<given-names><![CDATA[M,]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update]]></article-title>
<source><![CDATA[Ann Rheum Dis]]></source>
<year>2017</year>
<volume>76</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>960-77</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cavalli]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Dinarello]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anakinra Therapy for Non-cancer Inflammatory Diseases]]></article-title>
<source><![CDATA[Front Faramacol]]></source>
<year>2019</year>
<volume>8</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>148</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gadina]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Le]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[Schwartz]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Silvennoinen]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Nakayamada]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[O'Shea]]></surname>
<given-names><![CDATA[JJ,]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Janus kinases to jakinibs: from basic insights to clinical practice]]></article-title>
<source><![CDATA[Rheumatology]]></source>
<year>2019</year>
<volume>58</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>4-16</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
